Product | Doxorubicin Hydrochloride | |
Stock No | NS6130-12-000069 | |
CAS | 25316-40-9 | Confirm |
Purity | 99.9% | Confirm |
Molecular Weight | 810.3 g/mol | Confirm |
Melting Point | 216 ℃ | Confirm |
Boiling Point | 2950 °C | Confirm |
pH | 4.5 – 5.0 | Confirm |
MF | C27H29NO11 | Confirm |
Quality Control | Each Lot of was tested successfully | |
Main Inspect Verifier | Manager QC |
Assay | 99.9% |
Other Metal | 800ppm |
Doxorubicin Hydrochloride sold under the trade names Adriamycin among others, is a medication used in cancer chemotherapy. It is derived by chemical semisynthesis from a bacterial species. It is an anthracycline antitumor antibiotic (note: in this context, this does not mean it is used to treat bacterial infections) closely related to the natural product daunomycin and like all anthracyclines, it works by intercalating DNA, with the most serious adverse effect being life-threatening heart damage. It is commonly used in the treatment of a wide range of cancers, including hematological malignancies (blood cancers, like leukaemia and lymphoma), many types of carcinoma (solid tumours) and soft tissue sarcomas. It is often used in combination chemotherapy as a component of various chemotherapy regimens.
Naturally fluorescent anthracycline antibiotic, anticancer drug. Doxorubicin is a substrate of MRP1 which was first cloned from a DOX-resistant lung cancer cell line. Fluorescent property has been exploited for the measurement of drug efflux pump activities as well as resolving the important question of intracellular localization of various multidrug resistance proteins and the role of subcellular organelles (Golgi and lysosome) in the sequestration of drugs and its implication in drug resistant phenotypes.
Doxorubicin Hydrochloride is the hydrochloride salt of doxorubicin, an anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis. Additionally, doxorubicin inhibits topoisomerase II which results in an increased and stabilized cleavable enzyme-DNA linked complex during DNA replication and subsequently prevents the ligation of the nucleotide strand after double-strand breakage. Doxorubicin also forms oxygen free radicals resulting in cytotoxicity secondary to lipid peroxidation of cell membrane lipids; the formation of oxygen free radicals also contributes to the toxicity of the anthracycline antibiotics, namely the cardiac and cutaneous vascular effects.
Antimitotic and cytotoxic. Doxorubicin Hydrochloride has been used successfully to produce regression in a wide range of neoplastic conditions including acute leukaemia, lymphomas, soft-tissue and osteogenic sarcomas, paediatric malignancies and adult solid tumours; in particular breast and lung carcinomas. Doxorubicin is frequently used in combination chemotherapy regimens with other cytotoxic drugs. Doxorubicin cannot be used as an antibacterial agent.